Skip to main content

Table 2 Studies of passive immunization in newborn macaques

From: The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Treatment

Challenge

Sterile protection

References

Antibody (Route, Concentration)

Infusion timing

Virus

Route

SIV hyperimmune serum (SC, 20 mL/kg)

- Postnatal 2 days before challenge

SIVmac 251 (105 TCID50)

Oral

- 2/2

[1]

- Postnatal 2 days before challenge and 5 and 12 days after challenge

- 4/4

- Postanatal 3 weeks after challenge

- 0/3

- HIV immune globin (HIVIG) (IV, 400 mg/kg)

Postnatal 24 hours before challenge

SHIV89.6PD (40 TCID50)

IV

- 0/3

[3]

- 2F5 (IV, 15 mg/kg)

- 0/3

- 2G12 (IV, 15 mg/kg)

- 0/3

- 2F5 / 2G12 (IV, 15 mg/kg of each)

- 0/3

- HIVIG/2F5/2G12 (IV, 400 mg/kg of HIVIG, 15 mg/kg of each HuMoNAb)

- 3/6

F105/2G12/2F5 (IV, 10 mg/kg of each)

Pre- and postnatal 1–4 hours before and 8 days after challenge

SHIVIIIB-vpu+ (10 AID50)

Oral

4/4

[4]

2G12/b12/2 F5 (IV, 10 mg/kg of each)

Postnatal 1 hour before and 8 days after challenge

- SHIVIIIB-vpu+ (10 AID50)

Oral

- 2/2

[148]

- SHIV-89.6P (15 AID50)

- 1/4

F105/2G12/2F5 (IV, 10 mg/kg of each)

- Postnatal 3–4 hours before challenge and 8 days after challenge

SHIVIIIB-vpu+ (10 AID50)

Oral

- 2/2

[149]

- Postnatal 1 hour and 8 days after challenge

- 2/2

2G12/b12/2F5/4E10 (IV, 30 mg/kg of each except 4E10 at 11.5 mg/kg)

Postnatal 1 hour and 8 days after challenge

SHIV-89.6P (15 AID50)

Oral

2/4

[6]

2G12/2F5/4E10 (IM, 40 mg/kg of each)

Postnatal 1 hour and 8 days after challenge

SHIV-89.6P (15 AID50)

Oral

4/4

[150]

- 2G12/b12/2 F5/4E10 (IV, 30 mg/kg of each)

- Postnatal 1 hour and 8 days after challenge

SHIV-89.6P (15 AID50)

Oral

- 3/4

[151]

- Post natal 12 hours and 8 days after challenge

- 1/4

- 2G12/2F5/4E10 (IM, 40 mg/kg of each)

- Postnatal 24 hours and 9 days post challenge

- 0/4

  1. TCID50: 50% tissue culture infectious dose; AID50: 50% animal infectious dose.
  2. SC: subcutaneous; IV: intravenous; IM: intramuscular.